Entity Common Stock, Shares Outstanding of Mereo BioPharma Group plc from 31 Dec 2018 to 10 Nov 2025

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Mereo BioPharma Group plc quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 31 Dec 2018 to 10 Nov 2025.
  • Mereo BioPharma Group plc Entity Common Stock, Shares Outstanding for the quarter ending 10 Nov 2025 was 795,658,504, a 2.6% increase year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Mereo BioPharma Group plc Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 795,658,504 +19,930,470 +2.6% 10 Nov 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 795,484,404 +26,221,795 +3.4% 11 Aug 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 795,001,444 +93,714,415 +13% 25 Mar 2025 10-K 26 Mar 2025 2024 FY
Q3 2024 775,728,034 11 Nov 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 769,262,609 12 Aug 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 701,287,029 29 Feb 2024 10-K 27 Mar 2024 2023 FY
Q4 2022 624,928,519 +40,020,280 +6.8% 31 Dec 2022 20-F 28 Mar 2023 2022 FY
Q4 2021 584,908,239 +245,955,098 +73% 31 Dec 2021 20-F 31 Mar 2022 2021 FY
Q4 2020 338,953,141 +240,993,519 +246% 31 Dec 2020 20-F 31 Mar 2021 2020 FY
Q4 2019 97,959,622 +26,719,350 +38% 31 Dec 2019 20-F 15 Jun 2020 2019 FY
Q4 2018 71,240,272 31 Dec 2018 20-F/A 29 May 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.